46. Malignant rheumatoid arthritis
4,183 clinical trials,   2,538 drugs   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04068246 (ClinicalTrials.gov) | August 1, 2019 | 21/8/2019 | The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients | The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. | Rheumatoid Arthritis | Drug: Metformin;Drug: Placebo | Sadat City University | NULL | Recruiting | 18 Years | N/A | All | 150 | Early Phase 1 | Egypt |
2 | NCT02277574 (ClinicalTrials.gov) | June 2014 | 23/7/2014 | Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis | A Randomized, Multi-Dose, Placebo-Controlled, Study of the Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: AMP-110;Other: Placebo | MedImmune LLC | Daiichi Sankyo Co., Ltd. | Completed | 18 Years | 75 Years | Both | 29 | Phase 1 | United States |
3 | NCT01878123 (ClinicalTrials.gov) | April 2013 | 22/5/2013 | Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis | A Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: AMP-110;Other: Placebo | MedImmune LLC | Daiichi Sankyo Co., Ltd.;Daiichi Sankyo Co., Ltd. | Completed | 18 Years | 75 Years | Both | 26 | Phase 1 | United States |
4 | NCT01851278 (ClinicalTrials.gov) | April 2013 | 12/4/2013 | Effectiveness Intraarticular Corticosteroid | Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose | Rheumatoid Arthritis | Drug: Triamcinolone hexacetonide | Federal University of São Paulo | Fundação de Amparo à Pesquisa do Estado de São Paulo | Recruiting | 18 Years | 65 Years | Both | 60 | N/A | Brazil |
5 | NCT01151644 (ClinicalTrials.gov) | April 2010 | 25/6/2010 | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases | Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases | Rheumatoid Arthritis;Spondyloarthritis;Systemic Lupus Erythematosus (SLE);Dermatomyositis (DM);DMixed Connective Tissue Disease;Systemic Vasculitis;Systemic Sclerosis (SSc);Sjögren's Syndrome;Antiphospholipid Syndrome;Juvenile Idiopathic Arthritis;Juvenile SLE;Juvenile DM | Biological: Anti-pandemic H1N1 influenza vaccine | University of Sao Paulo | Fundação de Amparo à Pesquisa do Estado de São Paulo | Active, not recruiting | N/A | N/A | Both | 5000 | Phase 4 | Brazil |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
6 | NCT00239382 (ClinicalTrials.gov) | July 1, 2004 | 13/10/2005 | A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis | A Randomized, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 15 mg IM Ampoules Once Daily and Meloxicam 15 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With RA. | Arthritis, Rheumatoid | Drug: Meloxicam ampoule;Drug: Meloxicam tablet | Boehringer Ingelheim | NULL | Completed | 18 Years | N/A | All | 150 | Phase 3 | China |
7 | NCT02184052 (ClinicalTrials.gov) | July 2003 | 3/7/2014 | Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions | Meloxicam (MOBIC®) Ampoule Post Marketing Surveillance Study | Arthritis, Rheumatoid | Drug: Meloxicam | Boehringer Ingelheim | NULL | Completed | N/A | N/A | Both | 121 | N/A | NULL |